BioSpace News Archive

Daxor Corporation today announces it will be exhibiting at the Technology and Heart Failure Therapeutics Conference (THT), which brings together the world’s leading experts in heart failure innovations at the Westin Boston Seaport in Boston, Massachusetts March 4-6, 2024.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) today announced that David Mack, Ph.D., President and Chief Executive Officer of PMV Pharmaceuticals, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference taking place in Boston, Massachusetts March 4-6, 2024.

Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced completion of the single-ascending dose (SAD) cohorts for its phase 1, first-in-human clinical study of BT-600 in healthy adult volunteers.

NewAmsterdam Pharma Company N.V., a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol, for whom existing therapies are not sufficiently effective or well-tolerated, announced that company management will participate in three upcoming investor conferences.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.

Orchestra BioMed Holdings, Inc. announced the presentation of new data demonstrating the long-term effect of atrioventricular interval modulation therapy on generating clinically-meaningful reductions in 24-hour ambulatory systolic blood pressure in pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications.

Standard BioTools Inc. and Next Gen Diagnostics announce the execution of a long-term agreement aimed at revolutionizing the automation of sample preparation for pathogen whole genome sequencing.

IceCure Medical Ltd. announced new data from a preliminary, independent breast cancer study conducted by Principal Investigator and ProSense® user, Dr. Federica.

OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Wednesday, March 20, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

Pulmonx Announces Treatment of the First Patient with the AeriSeal ® System in CONVERT II Pivotal Trial.